Phase I Study of a Recombinant Attenuated Oncolytic Virus, MEDI5395 (NDV-GM-CSF), Administered Systemically in Combination with Durvalumab in Patients with Advanced Solid Tumors
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2024)
Key words
Pharmacokinetics - PK,Immune Checkpoint Inhibitor,Oncolytic virus
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined